{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:11:18Z","timestamp":1778343078534,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Noven Pharmaceuticals, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      <jats:sc>d<\/jats:sc>\n                      -Amphetamine transdermal system (\n                      <jats:sc>d<\/jats:sc>\n                      -ATS) is FDA-approved for treating attention-deficit\/hyperactivity disorder (ADHD) in adults and pediatric patients \u22656 years. In a pivotal study,\n                      <jats:sc>d<\/jats:sc>\n                      -ATS met its primary (SKAMP total score) and secondary endpoints. This analysis further evaluated\n                      <jats:sc>d<\/jats:sc>\n                      -ATS efficacy using SKAMP subscale scores and total score by subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The pivotal study comprised a 5-week, open-label dose-optimization period (DOP) followed by a 2-week, randomized, cross-over double-blind treatment period (DBP). All eligible patients received\n                      <jats:sc>d<\/jats:sc>\n                      -ATS 5 mg\/9 h, with weekly evaluation for dose increase and the optimal dose maintained during the DBP. Preplanned subgroup analyses of mean SKAMP total score in the DBP by optimized dose, sex, age group, ADHD type, and baseline ADHD severity were conducted. Efficacy was assessed by difference (\n                      <jats:sc>d<\/jats:sc>\n                      -ATS vs. placebo) in least-squares (LS) mean SKAMP total and subscale scores (Attention, Deportment, and Quality of Work) from a mixed-model repeated-measures (MMRM) analysis and is reported throughout as LS mean (95% confidence interval [CI]). Model-based effect sizes were calculated\n                      <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 110 patients were enrolled in the DOP; 106 were randomized in the DBP. The LS mean difference in SKAMP total score of\n                      <jats:sc>d<\/jats:sc>\n                      -ATS versus placebo was \u22125.9 (\u22126.8, \u22125.0), with differences in subscale scores (Attention, Deportment, and Quality of Work) of \u22121.4 (\u22121.7, \u22121.1), \u22121.9 (\u22122.2, \u22121.5), and \u22121.3 (\u22121.5, \u22121.0), respectively. Model-based effect sizes were 0.57, 0.42, 0.43, and 0.47, respectively. Patients receiving\n                      <jats:sc>d<\/jats:sc>\n                      -ATS demonstrated improvements versus placebo in LS mean SKAMP total score at each optimized dose in both male and female patients and children and adolescents and regardless of ADHD subtype or baseline ADHD severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Consistent efficacy of\n                      <jats:sc>d<\/jats:sc>\n                      -ATS across subgroups and all SKAMP subscale scores suggests broad utility of\n                      <jats:sc>d<\/jats:sc>\n                      -ATS in all patients, regardless of age, sex, ADHD type, or baseline ADHD severity, and broad applicability of these results to patients with varying clinical presentations of functional impairment by ADHD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10445463261434530","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:54:03Z","timestamp":1775192043000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>d<\/scp>\n                    -Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: SKAMP Subscale Analysis and Subgroup Analysis from a Pivotal Trial"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-0378","authenticated-orcid":false,"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[{"name":"SUNY Upstate Medical University and Neuroscience Education Institute, Lakewood Ranch, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Komaroff","sequence":"additional","affiliation":[{"name":"Product Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersy, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina","family":"Castelli","sequence":"additional","affiliation":[{"name":"Product Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersy, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Meeves","sequence":"additional","affiliation":[{"name":"Product Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersy, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahwish","family":"Khan","sequence":"additional","affiliation":[{"name":"Product Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersy, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1147558"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547211025610"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0176"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0078"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0109"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18nr12554"},{"issue":"4","key":"e_1_3_3_9_1","first-page":"437","article-title":"Systematic review of transdermal treatment options in attention-deficit\/hyperactivity disorder: Implications for use in adult patients","volume":"27","author":"Correll CU","year":"2022","unstructured":"Correll CU, , Starling BR, , Huss M. Systematic review of transdermal treatment options in attention-deficit\/hyperactivity disorder: Implications for use in adult patients. CNS Spectr 2022;27(4):437\u2013449.","journal-title":"CNS Spectr"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1917069"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1205"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0107"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0005"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/15374416.2017.1417860"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1460"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2022.0093"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0141-y"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S130444"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0077"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.7334\/psicothema2016.93"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1354648"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073191108326924"},{"key":"e_1_3_3_23_1","unstructured":"Noven Therapeutics LLC. FDA approves once-daily XELSTRYM\u2122 (dextroamphetamine) transdermal system CII for the treatment of attention-deficit\/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older. 2022 Available from: https:\/\/www.noven.com\/wp-content\/uploads\/2020\/02\/PR032322.pdf [Last accessed: August2 2024]."},{"issue":"3","key":"e_1_3_3_24_1","first-page":"PCC.13r01596","article-title":"A review of attention-deficit\/hyperactivity disorder in women and girls: Uncovering this hidden diagnosis","volume":"16","author":"Quinn PO","year":"2014","unstructured":"Quinn PO, , Madhoo M. A review of attention-deficit\/hyperactivity disorder in women and girls: Uncovering this hidden diagnosis. Prim Care Companion CNS Disord 2014;16(3):PCC.13r01596.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054714533191"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04188-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-8119(09)70075-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2019.00441"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7340a1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2015.03.007"},{"key":"e_1_3_3_31_1","volume-title":"School-based Assessments and Interventions for ADD Students","author":"Swanson JM","year":"1992","unstructured":"Swanson JM. School-based Assessments and Interventions for ADD Students. K.C. Publishing; 1992."},{"key":"e_1_3_3_32_1","unstructured":"US Center for Drug Evaluation and Research Office of Biostatistics. Statistical review and evaluation: NWP06 (Methylphenidate HCl) extended-release powder for oral suspension 25 mg\/5 mL. 2010. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/202100-Methylphenidate-Statistical-PREA.pdf [Last accessed: September8 2025]."},{"key":"e_1_3_3_33_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Statistical review and evaluation: Amphetamine Sulfate (AR11) Immediate Release (IR) Orally Disintegrating Tablets (ODT) 5 10 15 20 mg. 2018. Available from: https:\/\/www.fda.gov\/media\/148769\/download [Last accessed: September8 2025]."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0034"},{"issue":"1","key":"e_1_3_3_35_1","first-page":"47","article-title":"Reliability and validity of the SKAMP rating scale in a laboratory school setting","volume":"34","author":"Wigal SB","year":"1998","unstructured":"Wigal SB, , Gupta S, , Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34(1):47\u201353.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-3-17"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-4-32"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2019.01796"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0135-8"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.883"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.02.012"},{"key":"e_1_3_3_42_1","unstructured":"Xelstrym Prescribing Information. Xelstrym\u2122 (dextroamphetamine) transdermal system CII. 2025. Available from: https:\/\/www.xelstrym.com\/pdfs\/prescribing-information.pdf [Last accessed: December5 2025]."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1611145"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261434530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10445463261434530","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261434530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:46:12Z","timestamp":1778341572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10445463261434530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["10.1177\/10445463261434530"],"URL":"https:\/\/doi.org\/10.1177\/10445463261434530","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}